Game-Changing Drug Gives Stage 4 Breast Cancer Patients New Hope | Cancer Straight Talk

For nearly half of all breast cancer patients – those with low levels of the HER2 protein – targeted treatment options have always been limited. Palliative chemo has been the standard of care in stage 4 metastatic patients – until now. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Shanu Modi, the lead researcher of a groundbreaking MSK trial that proved a drug that combines an antibody with a chemotherapy – trastuzumab deruxtecan (T-DXd) – can control cancer cells and extend survival in stage 4 HER2-low breast cancer patients. With a fresh FDA approval, T-DXd is now being tested on other cancers and changing the way oncologists treat their patients. Learn more about breast cancer and its treatment: https://www.mskcc.org/cancer-care/typ... Originally published on Aug. 29, 2022 Find episode notes, transcripts, expert bios and more: https://bit.ly/3A83Dic Learn more about MSK: https://bit.ly/4qews1i Request an appointment at MSK by calling 844-955-1758 or online at: https://bit.ly/3MvaRTJ CONNECT WITH MSK o Facebook:   / memorialsloankettering   o X: https://x.com/mskcancercenter o Instagram:   / memorialsloankettering   o LinkedIn:   / memorial-sloan-kettering-cancer-center